Farmakoterapia w Psychiatrii i Neurologii
eISSN: 2449-9315
ISSN: 1234-8279
Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Recenzenci Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
Wyszukiwanie
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Bez opłat za publikację

without publication fees

Otwarty dostęp

without publication fees
1/2025
vol. 41
 
Poleć ten artykuł:
Wyślij znajomemu
Udostępnij:
Opis przypadku

Psychoza wywołana amantadyną u pacjenta z przewlekłą niewydolnością nerek – opis przypadku

Rafał Bieś
1
,
Maciej Niczewski
2
,
Ewa Martyniak
3
,
Jan Duława
2
,
Marek Krzystanek
3

  1. Doctoral School, Department and Clinic of Psychiatric Rehabilitation, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Katowice, Poland
  2. Department of Internal Medicine and Metabolic Diseases, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
  3. Clinic of Psychiatric Rehabilitation, Department of Psychiatry and Psychotherapy, Medical University of Silesia in Katowice, Katowice, Poland
Farmakoterapia w Psychiatrii i Neurologii 2025, 41 (1), 49-55
DOI: https://doi.org/10.5114/fpn.2025.154613
Data publikacji online: 2025/10/30
Plik artykułu:
- 5D0_IPiN_FARM_2025-1C.pdf  [0.11 MB]
Pobierz cytowanie
 
Metryki PlumX:
 
1. Carlsson A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 2006; 39 (Suppl 1): S10-4.
2. Chen JJ. Treatment of psychotic symptoms in patients with Parkinson disease. The mental health clinician 2018; 7 (6): 262-270.
3. Chinta SJ, Andersen JK. Dopaminergic neurons. The international journal of biochemistry & cel biology 2005; 37 (5): 942-6.
4. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clinical pharmacokinetics 2005; 41 (4): 261-309.
5. de Sousa Moreira JL, Barbosa SMB, Vieira JG, Chaves NCB, Felix EBG, Feitosa PWG, et al. The psychiatric and neuropsychiatric repercussions associated with severe infections of COVID-19 and other coronaviruses. Progress in neuro-psychopharmacology & biological psychiatry 2021; 106: 110159.
6. deVries T, Dentiste A, Di Lea C, Pichette V, Jacobs D. Effects of renal impairment on the pharmacokinetics of once-daily amantadine extended-release tablets. CNS Drugs 2019; 33 (8): 783-789.
7. Fryml LD, Williams KR, Pelic CG, Fox J, Sahlem G, Robert S, et al. The role of amantadine withdrawal in 3 cases of treatment-refractory altered mental status. Journal of psychiatric practice 2017; 23 (3): 191-199.
8. Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology 2012, 78 (14): 1096-9.
9. Krzystanek M, Pałasz A. Possibility of a new indication for amantadine in the treatment of bipolar depression-case series study. Pharmaceuticals (Basel, Switzerland) 2020, 13 (10): 326.
10. Krzystanek M, Warchala A, Trędzbor B, Martyniak E, Skałacka K, Pałasz A. Amantadine in the treatment of sexual inactivity in schizophrenia patients taking atypical antipsychotics – the pilot case series study. Pharmaceuticals (Basel, Switzerland) 2021, 14 (10): 947.
11. Liu P, Cheng PJ, Ing TS, Daugirdas JT, Jeevanandhan R, Soung LS, et al. In vitro binding of amantadine to plasma proteins. Clinical Neuropharmacology 1984; 7 (2): 149-51.
12. Ly D, DeLisi LE. Can antibiotics cause a psychosis?: Case report and review of the literature. Schizophrenia research 2017; 189: 204-207.
13. Marxreiter F, Winkler J, Uhl M, Madżar D. A case report of severe delirium after amantadine withdrawal. Case reports in neurology 2017; 9 (1): 44-48.
14. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. The Journal of neuroscience: the official journal of the Society for Neuroscience 1997; 17 (8): 2921-7.
15. Newcomer JW, Farber NB, Olney JW. NMDA receptor function, memory, and brain aging. Dialogues in clinical neuroscience 2000; 2 (3): 219-32.
16. Raupp-Barcaro IF, Vital MA, Galduróz JC, Andreatini R. Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials. Revista brasileira de psiquiatria 2018; 40 (4): 449-458.
17. Rosner MH, Husain-Syed F, Reis T, Ronco C, Vanholder R, 2022. Uremic encephalopathy. Kidney international 2022; 101 (2): 227-241.
18. Sławek J. Kliniczne znaczenie blokowania receptora NMDA. Polski przegląd Neurologiczny 2013; 9: 39-46.
19. Soung LS, Ing TS, Daugirdas JT, Wu MJ, Gandhi VC, Ivanovich PT, et al. Amantadine hydrochloride pharmacokinetics in hemodialysis patients. Annals of internal medicine 1980; 93 (1): 46-9.
20. Wilcox JA, Tsuang J. Psychological effects of amantadine on psychotic subjects. Neuropsychobiology 1990; 23 (3): 144-6.
21. Xu WJ, Wei N, Xu Y, Hu SH. Does amantadine induce acute psychosis? A case report and literature review. Neuropsychiatric disease and treatment 2016; 12: 781-3.

Termedia
O Wydawnictwie Oferty Newsletter Kontakt Praca
Polityka prywatności Polityka reklamowa Napisz do nas Nota prawna Regulamin
Na skróty
Mednauka Aktualności Czasopisma Książki eBooki Konferencje i webinary Podcasty
Serwisy
KONGRES TOP MEDICAL TRENDS Menedżer Zdrowia Lekarz POZ Choroby rzadkie Dermatologia Diabetologia Onkologia Neurologia Reumatologia Gastroenterologia Pulmonologia Ginekologia Kurier Medyczny Zalecenia i rekomendacje e-Praktyka Leczenia Ran Warto wiedzieć
e-Akademia
e-Akademia Zaburzeń Mikrobioty e-Akademia POChP e-Akademia Chorób Naczyń Akademia GLP-1
© 2025 Termedia Sp. z o.o.
Developed by Bentus.